Takeda Shores Up Pipeline Ahead Of Actos Patent Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma also conducting an “overall re-examination” of recently halted TAK-475 cholesterol drug.
You may also be interested in...
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Takeda submitted an NDA for its dipeptidyl peptidase-4 inhibitor alogliptin (SYR-322) for type 2 diabetes Dec. 27, potentially positioning the Japanese pharma to be second to market with a drug in the class